Competitor intelligence for pharma, ready in minutes.All your pharma intelligence
in one place.

From the primary record, never from a summary of it. Trial registries, regulators, financial filings and the companies' own announcements. Every fact carries its source and the date we read it, so an answer from ComplyRx can be checked.

Your watch is checked while you sleep. One morning email tells you what moved. The wider universe of trials, licences and filings refreshes on its own cycle, so what you see is never a snapshot from last quarter.

No. A chat window has no memory of the industry and starts from nothing every time. ComplyRx holds registry history back to 2022 and has checked every night since July 2026. It knows what a trial looked like before today's edit, which company sat behind a subsidiary last year, and which of forty names belongs to one molecule. AI helps you read it. The intelligence is in what we remember and connect.

The exact thing a competitor hoped you would not notice. A completion date that slipped. A primary endpoint quietly rewritten. A new country of sites. A status change. Each one a dated event with a before and an after, and each one scored against similar trials so you know whether it matters.

As one drug. Development codes, brand names, salts and the registry's own misspellings all resolve to a single record, so nothing slips a watch because someone typed it differently. This is the work that makes everything else possible, and no registry does it for you.

Yes. A trial run by a subsidiary appears under the parent you watch. Acquisitions, renames and joint ventures are tracked, so a competitor cannot hide behind a new letterhead.

Each announcement is matched to the trial it concerns and labelled with how the match was made, so you can judge it yourself. The point is timing: a company announces a result days or weeks before the registry catches up. ComplyRx puts the announcement next to the trial the moment it lands.

Yes, both. Licences and what each drug is approved to treat, on both sides of the Atlantic. One limit we state plainly: the European coverage is medicines approved centrally. Country-by-country approvals are on the roadmap.

We would rather show a gap than fill it with a guess. Molecular targets exist for about a quarter of drugs, because that is what the science has recorded. Company-guided readout dates from earnings calls are not stored yet. Where we have nothing, the page says so.

Yes. Sign up, describe what you want to monitor in a sentence, and your workspace is built for you: the drugs, the trials, the companies, the calendar. No contract, no demo, no enterprise onboarding.